

Supplementary Table 1. Demographic data and laboratory results of asymptomatic hemodialysis patients with preserved left ventricular ejection fraction

	cTnT >0.03 ng/ml (n=42)	cTnT ≤0.03 ng/ml (n=46)	p value
Age (years)	68.2 ± 10.7	65.4± 11.7	0.24
Male, n (%)	17 (39.5%)	15 (31.9%)	0.44
BMI (kg/m ²)	22.1± 2.7	21.3± 3.0	0.27
SBP (mmHg)	144.8 ± 16.1	148.2 ± 14.6	0.32
DBP (mmHg)	77.1 ± 9.9	77.0 ± 8.8	0.97
Hemodialysis duration (years)	6.0 ± 5.8	6.5 ± 4.6	0.68
Kt/V	1.65 ± 0.21	1.76 ± 0.24	0.10
IDWG (kgw)	2.84 ± 1.13	2.72 ± 0.95	0.77
IDWG (%)	5.1± 2.0	5.2 ± 1.7	0.61
Co-morbidities, number (%)			
CAD	18 (42.9%)	13 (28.3%)	0.15
Heart failure under control	7 (16.7%)	3 (6.5%)	0.18
Diabetes mellitus	28 (66.7%)	17 (37.0%)	0.005
Hypertension	37 (88.1%)	40 (87.0%)	0.87
LV hypertrophy	33 (78.6%)	35 (76.1%)	1.00
Cardiovascular drugs, number (%)			
CCB	26 (61.9%)	25 (54.3%)	0.47
β-Blocker	20 (47.6%)	22 (47.8%)	0.99

ACE inhibitors / A-II antagonists	20 (47.6%)	28 (60.9%)	0.21
Statin	7 (16.7%)	8 (17.3%)	0.93
Serum biochemistry study			
Calcium (mg/dL)	9.2 ± 0.7	9.3± 0.8	0.39
Phosphate (mg/dL)	4.3 ± 1.2	4.6 ± 1.4	0.43
Albumin (g/dL)	3.3 ± 0.4	3.4 ± 0.4	0.14
Cholesterol (mg/dL)	163.4 ± 40.0	162.8 ± 35.5	0.95
hs-CRP (mg/dL)	1.45 ± 2.04	0.57 ± 0.60	0.01
IL-6 (pg/mL)	12.8 ± 9.2	12.3 ± 8.8	0.81
PAI-1 (ng/ml)	158.3 ± 76.6	223.8 ± 195.0	0.06

Abbreviations: ACE, angiotensin-converting enzymes; A-II, angiotensin II; BMI, body mass index; CAD, coronary artery disease; CCB, calcium channel blocker; cTnT, cardiac troponin T; DBP, diastolic blood pressure; ESRD, end-stage renal disease; hs-CRP, high sensitivity C-reactive protein; IDWG, inter-dialytic weight gain; IL, interleukin; LV, left ventricular; PAI-1, plasminogen-activator inhibitor type 1; SBP, systolic blood pressure.

Data are expressed as mean ± SD or number (%).

Supplementary Table 2. Echocardiography results of asymptomatic hemodialysis patients with preserved left ventricular ejection fraction

	cTnT >0.03 ng/ml (n=42)	cTnT ≤0.03 ng/ml (n=46)	p value
LV EDVi (ml/m ²)	69.3 ± 18.3	70.8 ± 20.3	0.76
LV mass index (gm/m ²)	160.4 ± 67.6	137.3 ± 27.2	0.06
IVCe diameter (cm)	1.3 ± 0.3	1.2 ± 0.2	0.09
LV systolic function parameters			
LV EF (%)	63.0 ± 6.5	65.7 ± 5.1	0.07
Systolic myocardial velocity, s' (cm/sec)	8.2 ± 2.2	8.7 ± 1.7	0.23
GLS (%)	-16.4 ± 4.1	-19.6 ± 3.3	<0.001
Longitudinal SRs (sec ⁻¹)	-0.91 ± 0.21	-1.02 ± 0.22	0.03
CS (%)	-20.0 ± 6.0	-21.7 ± 6.0	0.24
Circumferential SRs (sec ⁻¹)	-1.89 ± 0.65	-1.95 ± 0.54	0.63
LV diastolic function parameters			
E (m/sec)	0.79 ± 0.31	0.81 ± 0.30	0.76
A (m/sec)	1.03 ± 0.36	1.04 ± 0.29	0.87
E/A	0.79 ± 0.33	0.83 ± 0.44	0.62
e' (cm/sec)	4.8 ± 1.3	4.9 ± 1.4	0.54
E/e'	16.7 ± 6.4	17.1 ± 8.5	0.80
LAVi (ml/m ²)	35.5 ± 8.6	35.0 ± 7.8	0.83

Abbreviations: CS, systolic circumferential strain; cTnT, cardiac troponin T; EDVi,

end-diastolic volume index; EF, ejection fraction; E/e', early trans-mitral velocity to tissue Doppler mitral annular early diastolic velocity ratio; GLS, global left ventricular peak systolic longitudinal strain; IVCe, end-expiratory inferior vena cava diameter; LAVi, left atrial volume index; LV, left ventricular; SRs, systolic strain rate

Data are expressed as mean \pm SD

Supplementary figure 1. Comparisons of left ventricular global peak systolic longitudinal strain (GLS) and global longitudinal strain rate (LSRs) in end-stage renal disease patients with either high cardiac troponin T (cTnT >0.03 ng/ml) or low cTnT (≤ 0.03 ng/ml) serum concentrations.

